natgillin/translations-raw huggingface dataset:
The efficacy of Dovato is supported by data from 2 identical 148-week, Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority controlled trials GEMINI-1 (204861) and GEMINI-2 (205543).
Učinkovitost zdravila Dovato potrjujejo podatki 2 identičnih, 148-tedenskih randomiziranih, dvojno slepih, multicentričnih, kontroliranih preskušanj neinferiornosti faze III z vzporednimi skupinami, GEMINI-1 (204861) in GEMINI-2 (205543).
Lamivudine triphosphate shows significantly less affinity for host cell DNA polymerases.
Lamivudin trifosfat ima občutno manjšo afiniteto do DNK polimeraz gostiteljske celice.
Preliminary data from a surveillance study has suggested an increased incidence of neural tube defects (0.9%) in mothers exposed to dolutegravir (a component of Dovato) at the time of conception compared with mothers exposed to non-dolutegravir containing regimens (0.1%).
Preliminarni podatki iz opazovalne študije so pokazali večjo incidenco okvar nevralne cevi (0,9 %) pri materah, ki so bile ob spočetju izpostavljene dolutegravirju (sestavina zdravila Dovato), v primerjavi z materami, ki so bile izpostavljene režimom, ki niso vsebovali dolutegravirja (0,1 %).
Lamivudine, via its active metabolite 5'-triphosphates (TP) (an analogue for cytidine), inhibits reverse transcriptase of HIV-1 and HIV-2 through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination.
Lamivudin preko svojih aktivnih presnovkov 5'-trifosfatov (TP) (analog citidina) zavira reverzno transkriptazo virusov HIV-1 in HIV-2 preko vključitve monofosfatne oblike v verigo virusne DNK, kar ima za posledico prekinitev verige.
Some late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Redko so poročali o nekaterih primerih nevroloških motenj, ki nastopijo kasneje (hipertonija, konvulzije, nenormalno obnašanje).
Carcinogenesis and mutagenesis
Karcinogenost in mutagenost
Reduction of the metformin dose should be highly considered.
Potreben je temeljit razmislek o zmanjšanju odmerka metformina.
Dolutegravir increased metformin concentrations.
Dolutegravir je povečal koncentracijo metformina.
Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study).
Dolutegravir se presnavlja predvsem preko glukoronidacije z UGT1A1 in v majhni meri s CYP3A (9,7 % skupnega odmerka, uporabljenega v študiji človeške masne bilance).
• sensation of weakness in the limbs.
• občutek šibkosti v udih
Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups.
Na splošno je bil varnostni profil pri bolnikih, ki so bili sočasno okuženi z virusom hepatitisa B in/ali C, podoben kot pri bolnikih brez sočasne okužbe z virusom hepatitisa B ali C, čeprav so bile stopnje nepravilnosti AST in ALT v podskupini s sočasno okužbo z virusom hepatitisa B in/ali C v vseh terapevtskih skupinah višje.
It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.
Ni znano, ali je vsa ta količina ali pa samo njen del neabsorbirana učinkovina ali pa je posledica biliarnega izločanja glukuronidnega konjugata, ki se v črevesni svetlini razgradi, tako da nastane osnovna spojina.
In vitro, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1.
In vitro dolutegravir ni bil substrat za humani OATP 1B1, OATP 1B3 ali OCT 1.
The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5-10%).
Verjetnost presnovnih interakcij z drugimi zdravili je majhna zaradi majhnega obsega jetrne presnove (od 5 do 10 %).
• metformin, to treat diabetes
• metformin, za zdravljenje sladkorne bolezni
• The other ingredients are microcrystalline cellulose, sodium starch glycolate, magnesium stearate, mannitol (E421), povidone (K29/32), sodium stearyl fumarate, hypromellose (E464), macrogol, titanium dioxide (E171).
• Druge sestavine zdravila so mikrokristalna celuloza, natrijev karboksimetilškrob, magnezijev stearat, manitol (E421), povidon (K29/32), natrijev stearilfumarat, hipromeloza (E464), makrogol, titanov dioksid (E171).
Dovato film-coated tablets are oval, biconvex, white tablets debossed with 'SV 137' on one face.
Dovato filmsko obložene tablete so ovalne, bikonveksne, bele tablete z vtisnjeno oznako 'SV 137' na eni strani.
Based on in vivo and/or in vitro data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).
Na podlagi in vivo in/ali in vitro podatkov ni pričakovati, da bi dolutegravir vplival na farmakokinetiko zdravil, ki so substrati glavnih encimov ali prenašalcev, kot so CYP3A4, CYP2C9 in P-gp (za več informacij glejte poglavje 5.2).
Delay in stopping treatment with Dovato or other suspect active substances after the onset of hypersensitivity may result in a life-threatening allergic reaction.
Odlašanje z ukinitvijo zdravljenja z zdravilom Dovato ali drugimi zadevnimi učinkovinami ob pojavu preobčutljivosti ima lahko za posledico življenjsko nevarno alergijsko reakcijo.
The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (<35 g/L) as seen in subjects with moderate hepatic impairment.
Delež nevezanega dolutegravirja v plazmi se pri nizkih vrednostih serumskega albumina (< 35 g/l) poveča, kar je opazno pri osebah z zmerno okvaro jeter.
A study of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment (CLcr <30 mL/min).
Študijo farmakokinetike dolutegravirja so izvedli pri preiskovancih s hudo okvaro ledvic (Clcr < 30 ml/min).
Marketing Authorisation Holder ViiV Healthcare BV Huis ter Heideweg 62
ViiV Healthcare BV Huis ter Heideweg 62
Some clinical findings also support a possible interaction between lamivudine and cladribine.
Nekatere klinične ugotovitve potrjujejo tudi možno medsebojno delovanje med lamivudinom in kladribinom.
If the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next dose is not due within 4 hours.
Če bolnik izpusti odmerek zdravila Dovato, ga mora vzeti čim prej, pod pogojem, da do naslednjega odmerka ni manj kot 4 ure.
The film-coated tablets are provided in bottles closed with child-resistant closures.
Filmsko obložene tablete so na voljo v vsebnikih, zaprtih z zaporko, varno za otroke.
Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).
Dvaintrideset odstotkov celotnega peroralnega odmerka se izloči z urinom, bodisi v obliki dolutegravirjevega glukuronida (18,9 % celotnega odmerka), metabolita N-dealkilacije (3,6 % celotnega odmerka) in metabolita, ki nastane z oksidacijo na benzilnem ogljiku (3,0 % celotnega odmerka).
If Dovato is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis.
Če pri bolnikih, ki so sočasno okuženi z virusom hepatitisa B, zdravilo Dovato ukinemo, je potrebno periodično spremljati tako teste jetrne funkcije kot označevalce replikacije virusa HBV, saj lahko ukinitev lamivudina vodi v akutno poslabšanje hepatitisa.
• breakdown of muscle tissue.
• razpad mišičnega tkiva
You may need extra checkups, including blood tests, while you're taking your medicine.
Morda boste med jemanjem tega zdravila potrebovali dodatne preglede, vključno s preiskavami krvi.
For Dovato, the median time to maximal plasma concentration (tmax) is 2.5 hours for dolutegravir and 1.0 hour for lamivudine, when dosed under fasted conditions.
Za zdravilo Dovato je mediani čas za dosego maksimalne koncentracije v plazmi (tmax) 2,5 ure za dolutegravir in 1,0 uro za lamivudin, pri uporabi na tešče.
There are no data available on the safety of lamivudine when administered to babies less than three months old.
O varnosti lamivudina, uporabljenega pri dojenčkih, mlajših od treh mesecev, ni podatkov.
Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14).
Podobne vrednosti IC50 so bile zabeležene pri kliničnih izolatih brez večjih razlik med podtipi; povprečna vrednost IC50 v panelu 24 izolatov HIV-1 podskupin A, B, C, D, E, F in G ter skupine O je bila 0,2 nM (razpon 0,02 - 2,14).
The IC50 values of lamivudine against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170 µM, against Group O from 0.030 to 0.160 µM and against HIV-2 isolates from 0.002 to 0.120 µM in peripheral blood mononuclear cells.
Vrednosti IC50 za lamivudin proti podtipom HIV-1 (A-G) so segale od 0,001 do 0,170 M, proti skupini O od 0,030 do 0,160 M in proti izolatom HIV-2 od 0,002 do 0,120 M v mononuklearnih celicah periferne krvi.
In vivo, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 or MATE-1 (e.g. metformin) (see Table 1 and section 4.3).
In vivo lahko dolutegravir zviša plazemske koncentracije zdravil, katerih izločanje je odvisno od OCT2 ali MATE-1 (npr. metformin) (glejte Preglednico 1 in poglavje 4.3).
• suicidal attempt (particularly in patients who have had depression or mental health problems before)
• poskus samomora (zlasti pri bolnikih, ki so že imeli depresijo ali težave z duševnim zdravjem)
If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Če je čas do naslednjega odmerka manj kot 4 ure, bolnik ne sme vzeti pozabljenega odmerka, ampak preprosto nadaljuje z jemanjem po ustaljenem urniku.
The stated reductions in dolutegravir exposure were observed with the intake of dolutegravir and these supplements during fasted conditions.
Navedena zmanjšanja v izpostavljenosti dolutegravirju so opazili pri jemanju dolutegravirja in teh dodatkov na tešče.
Oval, biconvex, white, film coated tablet, approximately 18.5 x 9.5 mm, debossed with “SV 137” on one face.
Ovalna, bikonveksna, bela, filmsko obložena tableta, velikosti približno 18,5 x 9,5 mm, ki ima na eni strani vtisnjeno oznako “SV 137”.
Other medicines and Dovato Tell your doctor if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
More than 1000 outcomes from second and third trimester exposure to dolutegravir in pregnant women indicate no evidence of increased risk of malformative and foeto/neonatal negative effects.
Več kot 1.000 primerov izpostavljenosti nosečnic dolutegravirju v drugem in tretjem trimesečju ne nakazuje dokazov o povečanem tveganju za deformacije in negativne učinke na plod/novorojenčka.
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1).
Zdravilo Dovato je indicirano za zdravljenje odraslih in mladostnikov, starejših od 12 let, ki tehtajo vsaj 40 kg, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), pri katerih ni znane ali domnevne odpornosti na skupino zaviralcev integraze ali na lamivudin (glejte poglavje 5.1).
In lactating rats that received a single oral dose of 50 mg/kg at 10 days postpartum, dolutegravir was detected in milk at concentrations typically higher than blood.
Pri podganah v laktaciji, ki so prejele enkratni peroralni odmerek 50 mg/kg 10. dan po kotitvi, so bile ugotovljene koncentracije dolutegravirja v mleku značilno višje od tistih v krvi.
In these cases the physician should refer to the individual product information for dolutegravir.
V takšnih primerih mora zdravnik upoštevati podatke o zdravilu, ki vsebuje dolutegravir.
Interaction studies have only been performed in adults.
Pediatrična populacija Študije medsebojnega delovanja so izvedli le pri odraslih.
The efficacy of Dovato, or the dual combination of dolutegravir plus lamivudine (as single entities) has not been studied in children or adolescents.
Učinkovitosti zdravila Dovato oziroma dvojne kombinacije dolutegravirja in lamivudina (kot v ločenih pripravkih) pri otrocih in mladostnikih niso raziskali.
• suicidal thoughts (particularly in patients who have had depression or mental health problems before).
• samomorilne misli (zlasti pri bolnikih, ki so že imeli depresijo ali težave z duševnim zdravjem).
Uncommon side effects that may show up in blood tests are:
Občasni neželeni učinki, ki se lahko pokažejo v preiskavah krvi, so:
Trimethoprim: AUC ↔
trimetoprim: AUC 
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).
Dolutegravir je tudi substrat za UGT1A3, UGT1A9, CYP3A4, P-glikoprotein (P-gp) in protein odpornosti pri raku dojke (BCRP).
As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical significance.
Ker ima odstranjevanje preko jeter pri očistku lamivudina manjšo vlogo, ni verjetno, da bi bila medsebojna delovanja zdravil zaradi zavrtja OCT1 klinično pomembna.
The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births (0.05-0.1%).
Incidenca okvar nevralne cevi pri splošni populaciji je od 0,5 primera do 1 primer na 1.000 živorojenih otrok (0,05 % - 0,1 %).
Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (< 1% of the dose).
Dolutegravir je prevladujoča spojina, ki kroži v plazmi, izločanje nespremenjene zdravilne učinkovine skozi ledvice je majhno (< 1 % odmerka).
Recommendations concerning coadministration
Priporočila glede sočasne uporabe
Opaque, white HDPE (high density polyethylene) bottles closed with child resistant polypropylene closures, with a polyethylene faced induction heat seal liner.
Neprosojni, beli vsebniki iz HDPE (polietilena visoke gostote) zaprti z za otroke varnimi polipropilenskimi pokrovčki, zapečateni s polietilensko folijo s pomočjo toplotne indukcije.
Don't stop unless your doctor tells you to.
Ne prenehajte z jemanjem, razen če vam to priporoči zdravnik.
But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time.
Če pa je čas do naslednjega odmerka manj kot 4 ure, izpustite pozabljeni odmerek in vzemite naslednjega ob običajnem času.
• phenytoin and phenobarbital, to treat epilepsy
• fenitoin in fenobarbital, za zdravljenje epilepsije
Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice.
Pri bolnikih z obstoječimi motnjami v delovanju jeter, vključno s kroničnim aktivnim hepatitisom, se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavljajo nepravilnosti v delovanju jeter, zato je treba take bolnike nadzorovati v skladu s standardno prakso.
Active renal secretion of lamivudine in the urine is mediated through the organic cation transporter (OCT) 2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K).
Aktivno ledvično izločanje lamivudina v urinu posreduje organski kationski prenašalec (OCT) 2 ter prenašalci za ekstruzijo več zdravil in toksinov (MATE1 in MATE2-K).
Dovato is indicated in the absence of documented or suspected resistance to the integrase inhibitor class and to lamivudine (see section 4.1).
Zdravilo Dovato je indicirano v odsotnosti dokazane ali domnevne odpornosti na skupino zaviralcev integraze in na lamivudin (glejte poglavje 4.1).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON (WITHOUT BLUE BOX - COMPONENT OF MULTIPACK)
VMESNA ŠKATLA (BREZ »BLUE BOX« - SESTAVNEGA DELA SKUPNEGA PAKIRANJA)
Don't take other medicines for the infection without your doctor's advice.
Brez zdravnikovega nasveta ne jemljite drugih zdravil za zdravljenje okužbe.
AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state.
AUC v cervikovaginalni tekočini, tkivu materničnega vratu in nožničnem tkivu je bila od 6 do 10 % ustrezne AUC v plazmi v stanju dinamičnega ravnovesja.
There have been reports of mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally to nucleoside analogues, these have predominantly concerned treatment with regimens containing zidovudine.
Obstajajo poročila o mitohondrijski disfunkciji pri HIV-negativnih dojenčkih, ki so bili in utero in/ali postnatalno izpostavljeni nukleozidnim analogom; ta so pretežno zadevala zdravljenje z režimi, ki vsebujejo zidovudin.
WOCBP who are taking Dovato should use effective contraception throughout treatment.
Ženske v rodni dobi, ki jemljejo zdravilo Dovato, morajo skozi celotno zdravljenje uporabljati učinkovito kontracepcijo.
Based on this data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of major enzymes or transporters (see section 4.5).
Na podlagi teh podatkov ni pričakovati, da bi dolutegravir vplival na farmakokinetiko zdravil, ki so substrati glavnih encimov ali prenašalcev (glejte poglavje 4.5).
The main adverse reactions reported are haematological disorders (anaemia, neutropenia), and metabolic disorders (hyperlactatemia, hyperlipasemia).
Glavni opisani neželeni učinki so hematološke motnje (anemija, nevtropenija) in presnovne motnje (hiperlaktatemija, hiperlipazemija).
Group O isolates from antiviral naïve patients tested for lamivudine activity were highly sensitive.
Izolati skupine O pri bolnikih, ki še niso dobivali protivirusnega zdravljenja, testirani za aktivnost lamivudina, so bili zelo občutljivi.
At baseline, in the pooled analysis, the median age of subjects was 33 years, 15% were female, 68% were white, 9% were CDC Stage 3 (AIDS), 20% had HIV-1 RNA >100,000 copies/mL, and 8% had CD4+ cell count less than 200 cells per mm3; these characteristics were similar between studies and treatment arms.
Izhodiščno je bila v združeni analizi mediana starost preiskovancev 33 let, 15 % je bilo žensk, 68 % je bilo belcev, 9 % je imelo stadij 3 po CDC (AIDS), 20 % je imelo HIV-1 RNK > 100.000 kopij/ml in 8 % je imelo število celic CD4+ manj kot 200 celic na mm
In fed state, the changes in exposure following intake together with calcium or iron supplements were modified by the food effect, resulting in an exposure similar to that obtained with dolutegravir administered in the fasted state.
Po hranjenju so bile spremembe v izpostavljenosti po hkratnem jemanju s kalcijevimi ali železovimi dodatki izničene z učinki hrane, kar je privedlo do podobne izpostavljenosti kot je bila izpostavljenost dolutegravirju, ki je bil apliciran na tešče.
There is no specific treatment for an overdose of Dovato.
Specifičnega zdravljenja pri prevelikem odmerjanju zdravila Dovato ni.
In vitro, dolutegravir demonstrated no direct, or weak inhibition (IC50>50 μM) of the enzymes cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP3A, UGT1A1 or UGT2B7, or the transporters Pgp, BCRP, BSEP, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, OCT1, MATE2-K, multidrug resistance-associated protein (MRP) 2 or MRP4.
In vitro dolutegravir ni pokazal neposrednega ali šibkega zaviralnega učinka (IC50 > 50 μM) na encime citokroma P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1 ali UGT2B7, ali na prenašalce Pgp, BCRP, BSEP, transportni polipeptid organskih anionov (OATP) 1B1, OATP1B3, OCT1, MATE2-K, z odpornostjo proti več zdravilom povezani protein (MRP) 2 ali MRP4.
Some medicines can affect how Dovato works or make it more likely that you will have side effects.
Nekatera zdravila lahko vplivajo na delovanje zdravila Dovato ali povečajo verjetnost, da se pri vas pojavijo neželeni učinki.
The carcinogenic potential of a combination of dolutegravir and lamivudine has not been tested.
Karcinogeni potencial kombinacije dolutegravir in lamivudin ni bil raziskan.
There are no data available on the effects of the combination of dolutegravir and lamivudine in animals.
Podatki o učinkih kombinacije dolutegravirja in lamivudina na živalih niso na voljo.
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.
Dolutegravir zavira HIV integrazo z vezavo na aktivno mesto integraze in preprečuje prenos zapisa pri vgradnji retrovirusne deoksiribonukleinske kisline (DNK), ki je bistvenega pomena za replikacijski ciklus HIV.
What Dovato looks like and contents of the pack
Izgled zdravila Dovato in vsebina pakiranja
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse reactions.
Pri bolnikih s kroničnim hepatitisom B ali C, ki se zdravijo s kombiniranim protiretrovirusnim zdravljenjem, obstaja večje tveganje za resne in potencialno smrtne neželene učinke, povezane z jetri.
Animal studies indicate no effects of dolutegravir or lamivudine on male or female fertility (see section 5.3).
Raziskave na živalih ne nakazujejo vpliva dolutegravirja ali lamivudina na plodnost pri moških ali ženskah (glejte poglavje 5.3).
Co-administration of Dovato and other medicinal products that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may, therefore, increase dolutegravir plasma concentration.
Sočasno jemanje zdravila Dovato in drugih zdravil, ki zavirajo UGT1A1, UGT1A3, UGT1A9, CYP3A4 in/ali P-gp, lahko poveča plazemske koncentracije dolutegravirja.
Hypersensitivity reactions have been reported with dolutegravir, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.
Poročali so o preobčutljivostnih reakcijah na dolutegravir, za katere so bili značilni izpuščaj, sistemski pojavi, včasih pa tudi motnje v delovanju organov, vključno s hudimi jetrnimi reakcijami.
Dolutegravir is eliminated mainly through metabolism by uridine diphosphate glucuronosyl transferase (UGT) 1A1.
Dolutegravir se izloča predvsem s presnovo preko uridindifosfat-glukuronozil transferaze (UGT) 1A1.
The absolute bioavailability of dolutegravir has not been established.
Absolutna biološka uporabnost dolutegravirja ni bila ugotovljena.
Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in vsebniku poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Lamivudine is also substrate of the hepatic uptake transporter OCT1.
Lamivudin je tudi substrat prenašalca jetrnega privzema OCT1.
As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.
Ker se dolutegravir v veliki meri veže na plazemske proteine, se ga z dializo verjetno ne da bistveno odstraniti.
• oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder
• okskarbazepin in karbamazepin, za zdravljenje epilepsije ali bipolarne motnje
Renal clearance of unchanged active substance is a minor pathway of elimination for dolutegravir.
Ledvični očistek nespremenjene zdravilne učinkovine je manj pomembna pot izločanja dolutegravirja.